Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells.

Shrestha, Ritu; Bridle, Kim R; Cao, Lu; Crawford, Darrell H G; Jayachandran, Aparna

Shrestha, Ritu; Bridle, Kim R; Cao, Lu; Crawford, Darrell H G; Jayachandran, Aparna.

Afiliación

Shrestha R; Faculty of Medicine, The University of Queensland, Brisbane, QLD 4120, Australia.
Bridle KR; Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia.
Cao L; Faculty of Medicine, The University of Queensland, Brisbane, QLD 4120, Australia.
Crawford DHG; Gallipoli Medical Research Institute, Greenslopes Private Hospital, Brisbane, QLD 4120, Australia.
Jayachandran A; Faculty of Medicine, The University of Queensland, Brisbane, QLD 4120, Australia.

Curr Oncol ; 28(3): 2150-2172, 2021 06 11.

Article en En | MEDLINE | ID: mdl-34208001

Asunto(s)

Carcinoma Hepatocelular; Neoplasias Hepáticas; Carcinoma Hepatocelular/tratamiento farmacológico; Carcinoma Hepatocelular/genética; Línea Celular Tumoral; Humanos; Neoplasias Hepáticas/tratamiento farmacológico; Neoplasias Hepáticas/genética; Recurrencia Local de Neoplasia; Células Madre Neoplásicas; Sorafenib/farmacología; Sorafenib/uso terapéutico

Palabras clave

cancer stem cells; epithelial-to-mesenchymal transition; hepatocellular carcinoma; immune checkpoint; sorafenib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Curr Oncol Año: 2021 Tipo del documento: Article País de afiliación: Australia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google